Patents by Inventor Jan Vavra

Jan Vavra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrugs of hydroxamate-based GCPII inhibitors
    Patent number: 11866394
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 9, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Mebendazole prodrugs with enhanced solubility and oral bioavailability
    Patent number: 11712435
    Abstract: Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: August 1, 2023
    Assignees: THE JOHNS HOPKINS UNIVERSITY, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Gregory Riggins, Pavel Majer, Tomas Tichy, Jan Vavra, Andrej Jancarik, Lukas Tenora
  • PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS
    Publication number: 20210355079
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 18, 2021
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Prodrug compositions and utility of hydroxamate-based GCPII inhibitors
    Patent number: 11059775
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 13, 2021
    Assignees: The Johns Hopkins University, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY
    Publication number: 20210205271
    Abstract: Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.
    Type: Application
    Filed: February 8, 2019
    Publication date: July 8, 2021
    Inventors: Barbara Slusher, Rana Rais, Gregory Riggins, Pavel Majer, Tomas Tichy, Jan Vavra, Andrej Jancarik
  • NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS
    Publication number: 20190352255
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Application
    Filed: November 20, 2017
    Publication date: November 21, 2019
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora